Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Tacrolimus
100%
Liver Transplant Recipients
100%
Single Center
100%
3-year Follow-up
100%
Steroid Minimization
100%
Liver Transplantation
83%
Basiliximab
66%
Steroid Avoidance
66%
Acute Rejection
33%
Steroid Withdrawal
33%
HBV Infection
33%
In(III)
16%
No Significant Difference
16%
Recurrence Rate
16%
Survival Rate
16%
Monotherapy
16%
Hepatocellular Carcinoma
16%
Hepatocellular Carcinoma Recurrence
16%
Adult Liver Transplantation
16%
Infection Rate
16%
Hepatitis B
16%
Hepatitis B Virus
16%
Graft Rejection
16%
China
16%
3-year Survival
16%
Immunosuppressive Protocols
16%
Medicine and Dentistry
Liver Transplantation
100%
Liver Graft
100%
Tacrolimus
85%
Basiliximab
57%
Hepatitis B Virus
57%
Infection
42%
Diseases
28%
Hepatocellular Carcinoma
28%
Recurrent Disease
14%
Acute Graft Rejection
14%
Recurrence Risk
14%
Survival Rate
14%
Immunosuppressive Drug
14%
Chronic Graft Rejection
14%
Hepatitis B
14%
Graft Rejection
14%
Monotherapy
14%
Side Effect
14%
Pharmacology, Toxicology and Pharmaceutical Science
Tacrolimus
100%
Hepatitis B Virus
66%
Basiliximab
66%
Infection
50%
Diseases
33%
Liver Cell Carcinoma
33%
Recurrent Disease
16%
Acute Graft Rejection
16%
Recurrence Risk
16%
Immunosuppressive Agent
16%
Survival Rate
16%
Monotherapy
16%
Hepatitis B
16%
Graft Rejection
16%
Chronic Graft Rejection
16%
Side Effect
16%
Immunology and Microbiology
Liver Transplantation
100%
Tacrolimus
85%
Hepatitis B Virus
57%
Basiliximab
57%
Infection
42%
Immunosuppressive Drug
14%
Acute Graft Rejection
14%
Survival Rate
14%
Chronic Graft Rejection
14%
Hepatitis B
14%